Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy

J Clin Oncol. 2014 Sep 1;32(25):e88-91. doi: 10.1200/JCO.2013.49.0599. Epub 2014 Feb 10.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / enzymology
  • Carcinoma, Ductal, Breast / genetics
  • Carcinoma, Ductal, Breast / pathology
  • Female
  • Humans
  • Inflammatory Breast Neoplasms / drug therapy*
  • Inflammatory Breast Neoplasms / enzymology
  • Inflammatory Breast Neoplasms / genetics*
  • Inflammatory Breast Neoplasms / pathology
  • Lapatinib
  • Middle Aged
  • Molecular Targeted Therapy
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / genetics*
  • Receptor, ErbB-2 / metabolism
  • Triple Negative Breast Neoplasms / drug therapy
  • Triple Negative Breast Neoplasms / enzymology
  • Triple Negative Breast Neoplasms / genetics
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Quinazolines
  • Lapatinib
  • ERBB2 protein, human
  • Receptor, ErbB-2